Today the European Patent Office (EPO) issued its decision on the validity of Amgen’s European patent covering PCSK9 antibodies, upholding Amgen’s patent in amended form. We intend to appeal today’s EPO decision, and we remain confident that the law and facts support our position.
This decision by the EPO is relevant only to this European patent, and is not binding on the national courts in Europe, but the decision may be taken into account by these courts. As we previously disclosed, Amgen has filed infringement lawsuits against Sanofi and Regeneron in Germany, France and the UK. The EPO proceedings run in parallel to the lawsuits in these countries.
We continue to believe that patients and physicians should have a choice of cholesterol-lowering therapies and that Praluent® (alirocumab) has a differentiated clinical profile. Data from the Praluent Phase 3 cardiovascular outcomes trial, ODYSSEY OUTCOMES, were recently published in The New England Journal of Medicine, describing the effect of Praluent in a trial of 18,924 patients who had a recent acute coronary syndrome (ACS), such as a heart attack.
Praluent inhibits the binding of PCSK9 (proprotein convertase subtilisin/kexin type 9) to the LDL (low density lipoprotein) receptor and thereby increases the number of available LDL receptors on the surface of liver cells to clear LDL, which lowers LDL-C levels in the blood. Praluent has been developed by Regeneron and Sanofi under a global collaboration agreement.
Praluent is approved in more than 60 countries worldwide, including the U.S., Japan, Canada, Switzerland, Mexico and Brazil, as well as the European Union (EU). In the U.S., Praluent is approved for use as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. In the European Union, Praluent is indicated in adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, as an adjunct to diet: a) in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or b) alone or in combination with other lipid-lowering therapies for patients who are statin-intolerant, or for whom a statin is contraindicated. The effect of Praluent on cardiovascular morbidity and mortality has not yet been determined.
Sanofi Media Relations Contact
+33 (0)1 53 77 46 46 - email@example.com
Sanofi Investor Relations Contact
+33 (0)1 53 77 45 45 - firstname.lastname@example.org
Regeneron Media Relations Contact
+1 (914) 847-5018 - Sarah.Cornhill@regeneron.com
Regeneron Investor Relations Contact
+1 (914) 847-3482 - Mark.Hudson@regeneron.com
Déclarations prospectives - Sanofi
Ce communiqué contient des déclarations prospectives. Ces déclarations ne constituent pas des faits historiques. Ces déclarations comprennent des projections et des estimations concernant la mise sur le marché et autre potentiel de ce produit, ou concernant les recettes futures envisagées pour ce produit. Ces déclarations prospectives peuvent souvent être identifiées par les mots « s'attendre à », « anticiper », « croire », « avoir l’intention de », « estimer », « planifier » ou « espérer», ainsi que par d’autres termes similaires. Bien que la direction de Sanofi estime que ces déclarations prospectives sont raisonnables, les investisseurs sont alertés sur le fait que ces déclarations prospectives sont soumises à de nombreux risques et incertitudes, difficilement prévisibles et généralement en dehors du contrôle de Sanofi, qui peuvent impliquer que les résultats et événements effectifs réalisés diffèrent significativement de ceux qui sont exprimés, induits ou prévus dans les informations et déclarations prospectives. Ces risques et incertitudes comprennent notamment les actions et contretemps réglementaires inattendus, ou généralement des réglementations étatiques, qui peuvent affecter la disponibilité ou le potentiel commercial de ce produit, l’absence de garantie que ce produit sera un succès commercial, les incertitudes inhérentes à la recherche et développement, les futures données cliniques et l’analyse des données cliniques existantes relatives à ce produit, y compris postérieures à la mise sur le marché, les problèmes inattendus de sécurité, de qualité ou de production, la concurrence de manière générale, les risques associés à la propriété intellectuelle, à tout litige en la matière et à l’issue de ces litiges, la volatilité des conditions économiques, ainsi que les risques qui sont développés ou identifiés dans les documents publics déposés par Sanofi auprès de l'AMF et de la SEC, y compris ceux énumérés dans les rubriques « Facteurs de risque » et « Déclarations prospectives » du document de référence 2018 de Sanofi, qui a été déposé auprès de l’AMF ainsi que dans les rubriques « Risk Factors » et « Cautionary Statement Concerning Forward-Looking Statements » du rapport annuel 2018 sur Form 20-F de Sanofi, qui a été déposé auprès de la SEC. Sanofi ne prend aucun engagement de mettre à jour les informations et déclarations prospectives sous réserve de la réglementation applicable notamment les articles 223-1 et suivants du règlement général de l’Autorité des marchés financiers.
Regeneron Forward-Looking Statements and Use of Digital Media
This statement includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, risks associated with intellectual property of other parties and pending or future litigation relating thereto, including without limitation the patent litigation pertaining to Praluent® (alirocumab) Injection discussed in this statement (as well as other patent litigation and related proceedings pertaining to Praluent), the ultimate outcome of any such proceedings, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition; the likelihood of success of any appeals relating to the court decision and injunction discussed in this statement; the nature, timing, and possible success and therapeutic applications of Regeneron's products, product candidates, and research and clinical programs now underway or planned, including without limitation Praluent; uncertainty of market acceptance and commercial success of Regeneron's products (such as Praluent) and product candidates; the availability and extent of reimbursement of the Company's products (such as Praluent) from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates and new indications for marketed products; unforeseen safety issues resulting from the administration of products and product candidates in patients, including serious complications or side effects in connection with the use of Regeneron's product candidates in clinical trials; the extent to which the results from the research and development programs conducted by Regeneron or its collaborators may be replicated in other studies and lead to therapeutic applications; ongoing regulatory obligations and oversight impacting Regeneron's marketed products (such as Praluent), research and clinical programs, and business, including those relating to patient privacy; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's products and product candidates, including without limitation Praluent; the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) on the commercial success of Regeneron's products and product candidates; competing drugs and product candidates that may be superior to Regeneron's products and product candidates; the ability of Regeneron to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron's collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; and the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical Industries Ltd. (or their respective affiliated companies, as applicable), to be cancelled or terminated without any further product success. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2018 and its Form 10-Q for the quarterly period ended June 30, 2019. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update publicly any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron’s media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed (http://twitter.com/regeneron).